The CCAAT/enhancer binding protein-␣ (C/EBP␣) is a transcription factor required for differentiation of myeloid progenitors. In addition to specific DNA binding, C/EBP␣ is also involved in proteinprotein interactions, some of which (p21, Cdk2/Cdk4, E2F) appear to be required for inhibition of proliferation and possibly differentiation. To investigate the mechanisms of C/EBP␣-induced granulocytic differentiation, we generated C/EBP␣ mutants reportedly defective in DNA binding, transactivation, and Cdk2/Cdk4 and E2F interaction and assessed their effects in a myeloid precursor cell line, primary bone marrow and C/EBP␣ knockout fetal liver precursor cells. We show here that the DNA binding-deficient Lys298Glu mutant, the E2F bindingdeficient basic region mutant 2 (BRM-2) carrying the Ile294Ala and Arg297Ala substitutions, and the transactivation-deficient N-terminus truncated p30 mutant all fail to promote differentiation on ectopic expression in myeloid precursor cells. By contrast, ectopic expression of the Cdk2/ Cdk4 interaction-deficient ⌬177-191 mutant promotes differentiation and induces gene expression as effectively as wildtype C/EBP␣. Thus, the integrity of the transactivation and DNA binding domains, but not of the Cdk2/Cdk4 interaction region, is necessary for C/EBP␣-induced differentiation. Since the E2F binding-deficient BRM-2 mutant interacted with E2F-1 but failed to activate gene expression, our results lend support to the hypothesis that activation of gene transcription is the determining factor in C/EBP␣-dependent differentiation.
Introduction
The CCAAT/enhancer binding protein-␣ (C/EBP␣) is a member of the bZIP (basic region leucine zipper) family of transcription regulators that includes C/EBP␤, C/EBP⑀, C/EBP␥, and C/EBP␦. C/EBP␣ family members form homodimeric and heterodimeric transcription factors via their C-terminal leucine zipper domains 1 and bind DNA as dimers via the adjacent basic regions. 2 Two distinct transactivation domains located in the N-terminal region distinguish the members of this family of transcription factors. C/EBP␣ expression promotes granulocytic differentiation of common myeloid precursors with a concomitant block of monocytic differentiation. 3 C/EBP␣ knock-out mice lack neutrophils and eosinophils but retain monocytes, and C/EBP␣-null fetal liver cells do not form colonies in response to granulocyte colony-stimulating factor (G-CSF). 4, 5 Indeed, C/EBP␣ knock-out cells lack receptors for G-CSF, and the restoration of both interleukin 6 (IL-6) and G-CSF receptor levels enables granulocytic differentiation in vitro. 6 The role of C/EBP␣ is, in part, independent of its effect on G-CSF receptor (G-CSFR) levels, as G-CSFR knock-out mice retain the production of mature granulocytes, whereas C/EBP␣ knock-out mice do not. 7 Recent studies have reported C/EBP␣ mutations in a significant number of patients with acute myelogenous leukemia (AML). Mutations in the N-terminus lead to the production of a truncated protein that appears to function as a dominant-negative (DN) inhibitor of the DNA binding and transactivation activity of the full-length protein. 8 A 30-kDa C/EBP␣ protein has been shown to be physiologically generated because of the use of an alternative translation initiation codon located 351 nucleotides downstream of the main AUG initiation codon. [9] [10] [11] This 30-kDa product also lacks the antimitotic activity exhibited by the full-length protein. 12 In another study performed in AML and myelodysplastic syndrome (MDS) patient samples, mutations affecting the bZIP domain of C/EBP␣ were found, but the predicted mutant proteins did not appear to have DN activity. 13 It has also been demonstrated that C/EBP␣ expression is suppressed at the translational level in BCR-ABL-expressing cell lines and in primary bone marrow cells from patients in chronic myelogenous (CML) blast crisis. 14 Ectopic expression of C/EBP␣ in BCR-ABL-expressing cells can overcome the block in granulocytic differentiation by promoting G-CSFinduced differentiation. 14 Likewise, in an animal model of AML, C/EBP␣ and ⑀ were shown to suppress the leukemic phenotype. 15 In normal myeloid progenitors, the differentiation-inducing function of C/EBP␣ is thought to depend on transcription activation of many differentiation-related genes such as the G-CSFR, myeloperoxidase (MPO), and neutrophil elastase (NE) genes. [16] [17] [18] Consistent with this, C/EBP␣ knock-out fetal liver cells lack G-CSFR expression. 19 There is also evidence that C/EBP-dependent transcription repression leads to down-regulation of c-Myc expression, allowing myeloid progenitor cells to undergo granulocytic differentiation. 20 In adipocyte precursor cells, the growth suppressive function of C/EBP␣ appears to be essential for its differentiation-inducing effect. It was initially proposed that the inhibition of proliferation was partly caused by C/EBP␣'s ability to activate transcription and induce posttranscriptional stabilization of p21. 21, 22 More recently, Wang et al 23 have shown that C/EBP␣ interacts with and inhibits Cdk2 and Cdk4 by preventing cyclin binding, independent of C/EBP␣'s DNA binding activity. The Cdk2/Cdk4 interaction domain of C/EBP␣ is located between amino acids 175 and 188 and is responsible for its growth inhibitory ability with no apparent effect on its transcriptional activation function. 23, 24 Furthermore, direct repression of E2F-dependent transcription by C/EBP␣ has been demonstrated, and mutation of the basic region was shown to abrogate the ability of C/EBP␣ to induce adipocyte differentiation. 25, 26 To investigate whether C/EBP␣ induces granulocytic differentiation via transcriptional regulation of target genes (eg, NE, G-CSFR) or by inhibition of proliferation, or both, we have generated mutants defective in these functions and assessed the differentiation-inducing potential of mutant proteins in a myeloid precursor cell line, in primary marrow cells, and in C/EBP␣ knock-out cells. We show here that a single amino acid mutation in the DNA binding region suppresses the ability of C/EBP␣ to induce granulocytic differentiation, concomitant with the abrogation of C/EBP␣-dependent gene induction. Deletion of the Cdk2/Cdk4 interaction region does not affect the differentiation-inducing activity of C/EBP␣ in all assay systems used. Mutation of the reported E2F binding site in C/EBP␣'s basic region also compromises the induction of differentiation; however, this mutant interacts with E2F-1 but is defective in transactivation and induction of gene expression. The p30 C/EBP␣ protein, which retains DNA binding but not transactivation activity, is completely defective in inducing granulocytic differentiation. These results suggest that the transactivation domain and the DNA binding/basic region of C/EBP␣ are necessary for granulocytic differentiation, whereas interaction with Cdk2/Cdk4 and perhaps with E2F is not. Moreover, these results lend support to the hypothesis that the transcription activation function of C/EBP␣ is the determining factor in C/EBP␣-dependent differentiation.
Materials and methods

Cell culture
The murine IL-3-dependent 32Dcl3 myeloid precursor cells were maintained in culture in Iscoves modified Dulbecco medium (IMDM) supplemented with 10% heat-inactivated fetal calf serum (FCS; Sigma Chemical, St Louis, MO), 2 mM L-glutamine (Gibco, BRL, Gaithersburg, MD), and 10% WEHI-conditioned medium as a source of IL-3. C/EBP␣ Ϫ/Ϫ cells derived from the fetal liver of C/EBP␣-deficient mice (kind gift of D. G. Tenen, Harvard Institutes of Medicine, Boston, MA) were maintained in IMDM supplemented with 15% FCS, 2% WEHI-conditioned medium, and 2% baby hamster kidney (BHK)-murine kit ligand (MKL)-conditioned medium (as a source of stem cell factor [SCF]). Normal murine marrow cells were obtained from the femurs of C57BL/6 mice after hypotonic lysis and enrichment for lineage-negative hematopoietic precursor cells using the standard StemSep protocol (StemCell Technologies, Vancouver, BC). Lineage-negative cells were 20% SCA1 ϩ and 75% CD34 ϩ and, prior to retroviral infection, were maintained for 2 days in IMDM supplemented with a cocktail of murine recombinant cytokines (2 ng/mL IL-3, 1.2 ng/mL IL-6, 10 ng/mL SCF [R&D Systems, Minneapolis, MN], 5 ng/mL granulocyte-macrophage colony-stimulating factor [GM-CSF], and 5 ng/mL Flt3/Flk2 ligand [StemCell Technologies]). 6:15 cells are an established 32D-BCR/ABL-transformed cell line that has lost endogenous C/EBP␣ and C/EBP␤ expression 14 (K.K., unpublished data, 2003).
Plasmids
⌬uORF/⌬spacer-C/EBP␣ ⌯〈 (p42 C/EBP␣). This plasmid was generated using an internal ribosome entry site-green fluorescent protein (IRES-GFP)-containing bicistronic retrovirus (MigR1) carrying the hemagglutinin A (HA)-tagged rat c/ebp␣ cDNA lacking the upstream open reading frame (ORF) and spacer regions as previously described. 14 BRM2-C/EBP␣ ⌯〈 (Lys298Glu). This mutant contains 2 amino acid substitutions (Ile294Ala and Arg297Ala) in rat C/EBP␣ and was generated by site-directed mutagenesis of ⌬UORF using the Quickeasy Mutagenesis system (Stratagene, La Jolla, CA).
Lys298Glu-C/EBP␣ ⌯〈 (Lys298Glu). This mutant, previously referred to as K300E, 24 which contains a single nucleotide change (892AϾG corresponding to amino acid 298 of the human C/EBP␣ protein [kindly provided by G. J. Darlington, Baylor College of Medicine, Houston, TX]), was released from the pcDNA3.1 vector using EcoRI and subcloned into the EcoRI site of MigR1.
⌬177-191-C/EBP␣ HA. This deletion construct was generated by ligating the polymerase chain reaction (PCR)-amplified C/EBP␣ cDNA segments upstream and downstream of the nucleotide sequences corresponding to amino acid 177 and 191, respectively. The primers used were (1) a 5Ј pMSCV primer that includes a XhoI restriction site, (2) a 3Ј primer 5Ј-GAGGCC-GGCCAGCGCCAG-3Ј ending at the sequence corresponding to amino acid 176, (3) a 5Ј primer 5Ј-GCGTCTCCCGCGCACTT-GGC-3Ј starting at the sequence corresponding to amino acid 192, and (4) a 3Ј primer corresponding to the sequence of the HA epitope followed by a stop codon and also including an EcoRI restriction site. The amplified fragments were digested with the XhoI and EcoRI restriction enzymes and subcloned into the XhoI-and EcoRI-digested MigR1 vector.
p30-C/EBP␣ ⌯〈. This plasmid, which encodes the N-terminaltruncated p30 C/EBP␣, was made by PCR amplification starting at the nucleotides corresponding to amino acid 118 of c/ebp␣ cDNA using a 5Ј primer (5Ј-ATGTCCGCGGGGGCGCACGG-3Ј) and a 3Ј primer corresponding to the sequence of the HA epitope followed by a stop codon and including an EcoRI restriction site. The PCR product was digested with EcoRI and subcloned into the HpaI-and EcoRI-digested MigR1 vector.
MigR1-Lys298Glu-Flag (Lys298Glu). To generate this plasmid, Lys298Glu was PCR-amplified using the 5Ј pMSCV primer and a 3Ј primer containing the 3Ј end of c/ebp␣ cDNA, the 24 bases Flag sequence followed by a stop codon sequence. The PCR product was digested with BamHI/ EcoRV and subcloned into the BglII/HpaI sites of the MigR1 vector. Each plasmid was sequenced to verify the presence of expected mutations.
pCMV-E2F1. This plasmid was a kind gift of Dr W. G. Kaelin (Dana-Farber Cancer Center, Boston, MA).
Differentiation analysis of retrovirally transduced myeloid precursor cells
For retroviral infections, Phoenix cells (kind gift of G. P. Nolan, Stanford University School of Medicine, Stanford, CA) were transiently transfected with the indicated plasmids. The infectious supernatant was collected 48 hours later and used to infect (a 48-hour procedure) parental 32Dcl3 cells, lineage-negative marrow cells, and C/EBP␣ Ϫ/Ϫ fetal liver myeloid progenitor cells as described. 27 Twenty-four hours later, infected cells were sorted (EPICS Profile Analyzer; Coulter, Hialeah, FL) for green fluorescent protein (GFP) expression. In 32Dcl3 cells and C/EBP␣ Ϫ/Ϫ cells, induction of differentiation was assessed after sorting in the presence of 10% U87-MG-conditioned medium alone (as a source of G-CSF) or 25 ng/mL recombinant G-CSF. 
RT-PCR reactions
For reverse transcriptase (RT)-PCR detection of neutrophil elastase (NE) transcripts, total RNA was extracted using Tri-Reagent (Sigma), and 1 g RNA was reverse-transcribed using 40 units avian myeloblastosis virus (AMV) reverse transcriptase (Roche Molecular Biochemicals, Indianapolis, IN), 200 M of each deoxynucleoside triphosphate (dNTP) and 0.25 U/mL random hexamers (Pharmacia, Uppsala, Sweden). cDNA was used as template for PCR (Expand High Fidelity PCR System; Roche) according to the manufacturer's protocol. The oligodeoxynucleotides specific for the amplification of murine NE were upstream primer (5Ј-ATGGCCCTTGGCA-GACTATCC-3Ј) and downstream primer (5Ј-GCCATTCTCGAAGATC-CCCTG-3Ј). As internal control, all cDNA samples were adjusted to yield relatively equal amplification of hnRNP E1 and/or GRB2. Control PCR reactions were run without template, and duplicates of each reaction were performed without reverse transcriptase.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were obtained from retrovirus-transduced cells by allowing the cells to swell in buffer A (20 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) [pH 7], 10 mM KCl, 2 mM MgCl 2 , 0.5% NP40, 1 mM phenylmethylsulfonylfluoride, and a protease inhibitor cocktail [Roche]) for 10 minutes on ice, homogenizing the cells by 5 strokes with a 26-gauge needle, sedimenting the nuclei by centrifugation for 3 minutes at 4000 rpm, and incubating the nuclear pellet in buffer B (buffer A plus 0.5 M NaCl) for 30 minutes at 4°C. EMSAs were performed by incubating 10 g nuclear extracts with 50 000 cpm of double-stranded 32 P-end-labeled oligonucleotide in a binding reaction mixture containing 10 mM HEPES (pH 7.9), 50 mM KCl, 2.5 mM MgCl 2 , 1 mM DTT (dichlorodiphenyltrichloroethane), 10% glycerol, 1 g acetylated bovine serum albumin, and 0.5 g poly(dI-dC) (Amersham Pharmacia Biotech, Piscatawy, NJ) at room temperature for 20 minutes. For the supershift assay, nuclear extracts were incubated with 1 g anti-C/EBP␣ antibody (rabbit polyclonal; Santa Cruz Biotechnologies, Santa Cruz, CA), for 15 minutes at room temperature following the addition of radiolabeled probe (50 000 rpm). Binding reactions were resolved on a 4% nondenaturing polyacrylamide gel in 1 ϫ Tris borate EDTA (ethylenediaminetetraacetic acid) (TBE) buffer and electrophoresed at 150 V for 2 hours. Gels were dried and exposed to autoradiography. The oligonucleotides used for the EMSAs were as follows: C/EBP␣ (neutrophil elastase promoter) 5Ј-TCGAGGC-CAGGATGGGGCAATACAACCC-3Ј and C/EBP␣ (G-CSF receptor promoter) 5Ј-AGGTGTTGCAATCCCCAGC-3Ј, both containing the binding site (underlined) for C/EBP␣.
Immunoprecipitation and Western blot analysis
293T cells were transiently cotransfected with p42 C/EBP␣ and Lys298Glu-Flag (single transfections also performed) or with E2F-1 and p42-, BRM-2-, or Lys298Glu-C/EBP␣. Cells were harvested 46 hours after transfection, washed once with 1 ϫ phosphate-buffered saline (PBS) and lysed (10 7 cells/100 L lysis buffer) in buffer containing (50 mM HEPES [pH 7.5], 150 mM NaCl, 0.5% NP40, 1 mM phenylmethyl sulfonyl fluoride [PMSF] supplemented with a cocktail of serine and cysteine protease inhibitors [complete, EDTA-free; Roche]) for 30 minutes, rotating at 4°C, and the lysates were clarified by centrifugation at 14 000 rpm for 10 minutes. Supernatants were precleared with 10 L 1:1 slurry of protein G plus agarose (Oncogene Research Products, Boston, MA) in lysis buffer. The precleared supernatants were incubated with 5 L Affinity Matrix HA (AFC-101P; Covance, Princeton, NJ) overnight, or the anti-HA (mouse monoclonal; Covance), the anti-Flag (M2; Sigma) antibodies with a 1:1 slurry protein G plus agarose for 4 to 5 hours rotating at 4°C. The beads were washed extensively (6 times) in lysis buffer containing 0.5% (anti-Flag), 0.05% (anti-HA), or 0.1% NP40 (anti-E2F-1), and the pellet was resuspended in 2 ϫ protein-loading buffer. Immunoprecipitated proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a nitrocellulose membrane, and immunoblotted using anti-HA, anti-Flag (M2 peroxidase conjugated; Sigma), anti-2F-1 (sc-251x; Santa Cruz), or anti-C/EBP␣ antibodies. Proteins were detected using enhanced chemiluminescence (ECL) (Amersham, Arlington Heights, IL).
Southern blot of RT-PCR products
PCR reactions for NE were carried for 22, 25, and 28 cycles and run on a 1.5% agarose gel. The gel was soaked for 30 minutes in 0.5 M NaOH, 1.5 M NaCl; 30 minutes in 1.5 M NaCl, 1 M Tris, pH 7.5; and 15 minutes in 20 ϫ sodium saline citrate (SSC). The PCR products were then transferred onto Hybond-Nϩ filter (Amersham) overnight, and the DNA was then UV-fixed to the filter. The filter was prehybridized at 50°C for 2 hours in 5 ϫ SSC, 1 ϫ Denhardt solution, 0.1% SDS, and 100 g/mL sheared salmon sperm DNA. An internal NE oligonucleotide located 40 base pair (bp) upstream of the ATG (5Ј-CCAGGAACA-ATGCCAGTAGCAT-3Ј) was ␥-32 P-ATPlabeled, purified through a G-25 Sephadex column, and 1 ϫ 10 6 cpm/mL used for hybridization overnight at 50°C in 5 ϫ SSC, 0.1% SDS, and 100 g/mL sheared salmon sperm DNA. The filter was washed in 2 ϫ SSC, 0.1% SDS (3 times for 15 minutes at room temperature and for 15 minutes at 50°C), and exposed to X-AR imaging films (Eastman Kodak, Rochester, NY) at Ϫ80°C overnight.
Luciferase assay
Both 293T and NIH3T3 cells were used in this assay. Briefly, cells were transiently transfected using Fugene 6 reagent (Roche) according to the manufacturer's protocol with 50 ng reporter construct pTK-G-CSFRluciferase (firefly) (kind gift of D. G. Tenen, Harvard Institutes of Medicine) and 100 ng of the indicated C/EBP␣ expression plasmid. The reporter plasmid contains 4 consensus C/EBP␣ binding sites from the G-CSF receptor promoter. 19 As a control, a renilla reporter construct, which contains 4 mutated C/EBP␣ consensus binding sites, was also used. Twenty-four hours after transfection, firefly and renilla luciferase activity was recorded on a luminometer using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Results are presented as the percentage luciferase (firefly) and renilla activity relative to values obtained using p42 C/EBP␣ (assigned 100% luciferase/renilla activity) Ϯ SEM, and are representative of 4 individual experiments (performed in duplicate).
Cell cycle analysis
Cells (0.2-0.5 ϫ 10 6 /sample) were washed in 1mL 1 ϫ PBS/5 mM EDTA and fixed by slowly adding ice-cold 100% ethanol to give a final concentration of 70% and incubated on ice for 20 minutes. Cells were washed in PBS and incubated in 0.5 mL PBS containing 200 g/mL DNase-free RNase A for 30 minutes at room temperature. Propidium iodide was then added to a final concentration of 50 g/mL and incubated for at least 15 minutes at room temperature in the dark, and samples were then analyzed by Flow Cytometry (EPICS Profile Analyzer; Coulter).
Results
C/EBP␣ accelerates G-CSF-driven differentiation of 32Dcl3 myeloid precursor cells
Myeloid precursor 32Dcl3 cells are IL-3 dependent for growth and undergo terminal differentiation on G-CSF treatment. To assess the effect of ectopic C/EBP␣ expression on G-CSF-driven differentiation, 32Dc13 cells were retrovirally infected with MigR1-p42 C/EBP␣, an IRES-GFP-containing retrovirus encoding the 42-kDa wild-type C/EBP␣ protein, or MigR1 alone in the presence of IL-3. Twenty-four hours after infection, homogenous GFP-positive cells were selected by flow cytometry and cultured in the presence of IL-3 or G-CSF for the indicated time. In the presence of IL-3, C/EBP␣ was unable to induce terminal differentiation (Figure 1 ). By contrast, most 32D-p42 C/EBP␣ cells (approximately 55% in 3 different experiments) underwent terminal differentiation when cultured in the presence of G-CSF for 3 days, whereas the control 32D-MigR1 cells displayed only early signs of differentiation (Figure 1) . Thus, ectopic expression of p42 C/EBP␣ accelerates GCSF-induced granulocytic differentiation of 32Dcl3 cells.
Transcriptional activation function of C/EBP␣ is necessary for granulocytic differentiation
To identify the domains necessary for the differentiation-inducing function of C/EBP␣, we generated several C/EBP␣ mutants ( Figure 2A) and assessed the effects of ectopic expression in myeloid precursor cells ( Figure 2B-C) . The Lys298Glu-C/EBP␣ mutant (previously referred to as K300E 24 ), containing a single amino acid mutation (Lys298Glu) in the basic region/DNA binding domain, maintains the ␣-helical structure but is defective in DNA binding. Basic region mutant-2 (BRM-2) has a double mutation (Ile294Ala and Arg297Ala) of residues that are on the non-DNA binding face of the basic region ␣-helix that, according to Porse et al, 26 renders it defective in E2F binding. ⌬177-191 is a C/EBP␣ internal deletion mutant which fails to interact with Cdk2/Cdk4. 23 p30-C/EBP␣ encodes for an N-terminal-truncated mutant protein which lacks the transactivation domain 12 (Figure 2A) . Each of these mutants was subcloned into the MigR1 retrovirus.
To assess their differentiation potential, the wild-type (WT) or mutant C/EBP␣ retrovirus was transduced in 32Dcl3 cells grown in the presence of IL-3. Following isolation of GFP-positive cells, ectopic expression of WT or mutant C/EBP␣ was assessed by anti-HA Western blotting ( Figure 2B) , and transduced cells were cultured in the presence of G-CSF for 3 days. GFP positivity was tested in cells cultured for 24 hours and ranged from 85% to 95%. The lowest GFP positivity was typically found in cultures of p42 C/EBP␣-expressing cells. p42 C/EBP␣ and ⌬177-191 was able to induce terminal differentiation, as indicated by the appearance of polymorphonucleated neutrophils (approximately 54% and 56%, respectively) on cytospin preparations ( Figure 2C, upper row) , but the Lys298Glu, BRM-2, and p30 C/EBP␣ mutants did not ( Figure  2C , upper row). To further assess the differentiation-inducing potential of these C/EBP␣ mutants, we performed the differentiation assay in primary murine hematopoietic precursor marrow cells depleted of lineage-committed cells (20% SCA1 ϩ and 75% CD34 ϩ ). Following lineage-negative selection, these cells were retrovirally infected with WT or mutant C/EBP␣ for 48 hours, selected for GFP positivity, and assessed for granulocytic differentiation. Retrovirustransduced cells were cultured in the presence of a cocktail of murine cytokines (IL-6, Flt3/Flk2 ligand, SCF, GM-CSF, and IL-3) to maintain precursor cells. In the absence of G-CSF, 80% and 77% (the average of 3 independent experiments) of WT C/EBP␣-and ⌬177-191-expressing cells underwent granulocytic differentiation ( Figure 2C, lower row) ; by contrast, only 19% of MigRItransduced cells did undergo differentiation ( Figure 2C , lower row). Similar to our results in 32D cells, the Lys298Glu, BRM-2, and p30 mutants were unable to induce differentiation (Ͻ 10%), as retrovirus-transduced cells retained the morphologic features of lineage-negative precursor cells ( Figure 2C, lower row) . Because the ⌬177-191-C/EBP␣ mutant is reportedly defective in Cdk2 binding and yet enables differentiation of myeloid precursor cells, it seems that DNA binding and transcription activation (not Cdk2 binding) is necessary for C/EBP␣-dependent granulocytic differentiation.
The DNA binding ability of each mutant was tested in 6:15 (32D-BCR/ABL) cells, because these cells no longer express endogenous C/EBP␣ and C/EBP␤ 14 (K.K., unpublished data, 2003), thereby allowing the assessment of ectopic C/EBP␣ activity without any background. On retroviral infection of 6:15 cells with each of the MigR1 C/EBP␣ mutants and selection of GFP-positive cells in the presence of IL-3, nuclear extracts were prepared and analyzed by electrophoresis mobility shift assays (EMSAs) using radiolabeled G-CSFR ( Figure 3A) and NE ( Figure 3B-C) probes. p42 C/EBP␣, ⌬177-191, BRM-2, and p30 C/EBP␣ proteins bound specifically to the probes (Figure 3, lanes 4, 8, 10, and 12) , whereas Lys298Glu did not (Figure 3, lane 6 ). Of note, p30 bound to the G-CSFR C/EBP binding site less efficiently than to the NE C/EBP binding site, as previously shown. 8 No binding was detected with nuclear extracts from cells transduced with MigR1 alone (Figure 3 , lane 2). Binding was confirmed by competition experiments with excess of cold oligonucleotides (data not shown). Moreover, addition of the anti-C/EBP␣ antibody specifically supershifted the C/EBP␣-containing DNA-protein complex (Figure 3, lanes 5, 9,  11, and 13) . Similar data were obtained in EMSA performed with nuclear extracts of 293T cells transfected with WT or mutant C/EBP␣ ( Figure 3C ). Thus, a single mutation (Lys298Glu) in the basic region/DNA binding domain of C/EBP␣ prevents DNA binding, while this activity is retained by the mutants ⌬177-191 (which does not interact with Cdk2/Cdk4) and BRM-2 (which is supposedly defective in E2F binding).
We next analyzed the transactivation potential of each of the C/EBP␣ mutants by using a reporter plasmid in which expression of the luciferase gene is driven by a minimal thymidine kinase promoter linked to 4 C/EBP␣ binding sites from the G-CSFR-5Ј flanking sequence. 19 We cotransfected 293T cells with WT or mutant C/EBP␣ along with the luciferase reporter plasmid, and 24 hours later protein extracts were assessed for luciferase activity. The assays revealed that p42 (WT) and ⌬177-191 were able to transactivate luciferase expression, whereas the Lys298Glu and p30 mutants did not. The BRM-2 mutant had only a modest transactivating effect ( Figure 4A, top panel) . There was no transactivation in cotransfection experiments performed with a renilla reporter plasmid containing mutated G-CSFR-derived C/EBP␣ binding sites ( Figure 4A, inset) . That the p30 and Lys298Glu mutants were unable to transactivate luciferase activity is not surprising because p30 lacks the transactivation domain and Lys298Glu is deficient in DNA binding (Figures 3 and 4A) . Instead, it was surprising that the BRM-2 mutant was deficient in transactivation function despite its ability to bind DNA in a sequence-specific manner. Thus, we further explored the transcription activation potential of C/EBP␣ mutants by assessing the expression of NE in retrovirally transduced and GFP-sorted 32Dcl3 cells. Total RNA from cells maintained in the presence of IL-3 was assessed for NE expression at day 0 and day 3. This allowed us to assess gene induction as a function of C/EBP␣ activity rather than as a marker of differentiation. p42 C/EBP␣ and the ⌬177-191 mutant were capable of NE gene induction at day 0 and day 3, whereas the C/EBP␣ mutants Lys298Glu and p30 were not ( Figure  4B ). The BRM2 mutant had a modest effect at day 0, but NE transcripts were undetectable at day 3 ( Figure 4B ). Similar results were obtained on testing mRNA levels of G-CSFR and myeloblastin, 2 other C/EBP␣-regulated genes. 19, 28 Thus, C/EBP␣-dependent gene expression requires DNA binding and transactivation (demonstrated by the Lys298Glu, BRM-2, and p30 mutants), whereas mutation of the Cdk2 binding site does not abolish C/EBP␣-dependent gene induction.
Potential mechanisms in the block of granulocytic differentiation by C/EBP␣ Lys298Glu and C/EBP␣ BRM-2 mutants
To assess potential mechanisms whereby ectopic expression of Lys298Glu and BRM-2 C/EBP␣ mutants interferes with G-CSFinduced differentiation of 32Dcl3 cells, we assessed the cell cycle distribution of G-CSF-treated retrovirally transduced 32Dcl3 cells. 
G-CSF-driven differentiation of 32Dcl3 cells transduced with
MigR1 or p42 C/EBP␣ led to a reduction in the number of S phase cells and a concomitant increase in the number of G1 phase cells. By contrast, cells ectopically expressing the Lys298Glu DNA binding-deficient mutant underwent cell death as indicated by the fraction with sub-G1 DNA content (Lys298Glu, G1 ϭ 37%; sub-G1 ϭ 45%) ( Figure 5A ). Comparable effects on apoptosis induction were obtained by ectopic expression of BRM-2 (BRM-2, G1 ϭ 47%; sub-G1 ϭ 49%).
The induction of apoptosis in G-CSF-treated Lys298Glu-expressing 32Dcl3 cells might be due to inhibition of the wild-type C/EBP␣ function that would be required for differentiation of G1-arrested cells. Thus, we tested the formation of p42-Lys298Glu heterodimers by coimmunoprecipitation experiments. On coexpression of HA-tagged p42 C/EBP␣ and Flag-tagged Lys298Glu in 293T cells, p42 and Lys298Glu-C/EBP␣ were found in complex ( Figure 5B), consistent with the possibility that mutant C/EBP␣ inhibits the activity of the endogenous C/EBP␣ by forming a nonfunctional heterodimer. Induction of apoptosis by BRM-2 C/EBP␣ may be a consequence of its reported defect in E2F interaction, which would allow free E2F-1 to induce apoptosis. Indeed, ectopic expression of E2F-1 induces apoptosis of G-CSFtreated 32Dcl3 cells. 29 Thus, we tested whether E2F-1 interacts with BRM-2 C/EBP␣. On coexpression of E2F-1 with p42 or BRM-2 C/EBP␣, we found that E2F-1 was able to form a complex with both proteins (Figure 5C ), suggesting that BRM-2 C/EBP␣ does not block differentiation and induce apoptosis via E2F-1. As expected, Lys298Glu C/EBP␣ was found in complex with E2F-1 ( Figure 5C ).
Although the BRM-2 mutant interacts with the C/EBP␣ binding sites in the NE promoter (as indicated by the supershift in Figure 3) , its ectopic expression prevents NE mRNA up-regulation in 32Dcl3 cells treated with IL-3 or G-CSF ( Figure 6A ). Thus, we carried out additional EMSAs with an excess of competitor oligonucleotides to test whether p42 and BRM-2 C/EBP␣ bound the radiolabeled C/EBP␣ binding sites in the NE promoter with similar or different affinity. Such analysis suggests that there are no differences in binding affinity ( Figure 6B) ; however, the C/EBP␣-BRM-2-DNA complex had a slower mobility than that formed with WT C/EBP␣. It remains to be demonstrated if this reflects an altered protein complex and if it is relevant for the block of differentiation by the BRM-2 mutant.
Ectopic C/EBP␣ expression can induce differentiation of G-CSF-treated C/EBP␣ knock-out cells
32Dcl3 cells express endogenous C/EBP␣, which in conjunction with G-CSF-dependent signals, is instrumental for granulocytic differentiation. To further assess the effects of WT and mutant C/EBP␣ in a cell context in which there is no interference by endogenous C/EBP␣, C/EBP␣-dependent gene expression and differentiation were tested in retrovirally transduced C/EBP␣ knock-out (C/EBP␣ Ϫ/Ϫ ) cells. 30 For gene expression studies, total RNA was isolated from GFP-positive cells, and RT-PCR was performed to monitor possible changes in NE mRNA transcript levels. Southern hybridization of the PCR products using an internal NE probe demonstrated linear upregulation (at 22 and 25 cycles) of NE mRNAlevels in C/EBP␣ Ϫ/Ϫ -p42-transduced cells and lack of expression in C/EBP␣ Ϫ/Ϫ -Lys298Glu, C/EBP␣ Ϫ/Ϫ -BRM-2, and parental C/EBP␣ Ϫ/Ϫ cells ( Figure 7A , top 2 panels). Amplified cDNA copies of NE mRNA transcripts were detectable on the agarose gel after 28 cycles ( Figure 7A, lower panel) . NE mRNA transcripts were amplified from cells grown in the absence of G-CSF, thereby demonstrating specific C/EBP␣-dependent gene induction.
The C/EBP␣ knock-out (C/EBP␣ Ϫ/Ϫ ) cells were then used to further assess the role of WT and mutant C-EBP␣ in granulocytic differentiation, as these cells do not undergo differentiation following G-CSF treatment ( Figure 7B, left panels) . Thus, cells transduced with WT or mutant C/EBP␣ were selected by GFP positivity (day 0) and assessed for morphologic differentiation in the presence of G-CSF. Consistent with the findings in 32Dcl3 and lineage-negative myeloid precursors, C/EBP␣ Ϫ/Ϫ -p42 and C/EBP␣ Ϫ/Ϫ -⌬177-191 cells underwent terminal differentiation (77% and 75%, respectively, in 3 independent experiments), whereas C/EBP␣ Ϫ/Ϫ -Lys298Glu and C/EBP␣ Ϫ/Ϫ -BRM-2 cells remained undifferentiated ( Figure 7B ). In IL-3-supplemented cultures, only p42 C/EBP␣ had a modest effect (approximately 10% in 3 independent experiments). Thus, Cdk2 binding does not seem to be important for C/EBP␣-dependent gene expression and differentiation, whereas abrogation of DNA binding and gene induction capability through mutation of the basic region/DNA binding domain severely compromises C/EBP␣ potential to induce granulocytic differentiation.
Discussion
In this paper, we have attempted to dissect the domains of C/EBP␣ that are required for granulocytic differentiation. Evidence suggests that the differentiation-inducing effect of C/EBP␣ is determined by its ability to modulate gene expression, by its growth suppressive function that appears to depend on protein-protein interactions (reviewed in McKnight 31 ), or by both. We have assessed the ability of C/EBP␣ mutants that are unable to transactivate gene expression (p30) or bind DNA (Lys298Glu), or are defective in interaction with Cdk2/Cdk4 (⌬177-191) or E2F (BRM-2), to induce granulocytic differentiation. Our findings indicate that p42 C/EBP␣ and the ⌬177-191 mutant were capable of inducing neutrophilic differentiation, whereas the mutants Lys298Glu, BRM-2, and the N-terminus truncated p30 were not, in 32Dcl3 cells, in lineagenegative primary bone marrow cells, and in fetal liver C/EBP␣ knock-out cells. Our data suggest that several requirements need to be met for C/EBP␣-dependent granulocytic differentiation. 1-7) or p42 C/EBP␣ (lanes [8] [9] [10] [11] [12] [13] [14] and the NE probe (wild-type or mutant) in the absence (lanes 1 and 8) or in the presence (lanes 2-6 and 9-13) of a 2-to 50-molar excess of a wild-type NE oligonucleotide used as competitor. In lanes 7 and 14, EMSAs were performed with a 32 P-labeled mutant NE oligonucleotide. In this study, ectopic expression of wild-type C/EBP␣ failed to induce differentiation of 32Dcl3 cells growing in IL-3 ( Figure 1 ). This finding contrasts with a previous study of Wang et al 32 that reported induction of differentiation by the ␤-estradiol-regulated C/EBP␣-ER chimera. This raises the possibility that the different effects of C/EBP␣ in 32Dcl3 cells cultured in IL-3 might, in part, depend on the properties of the plasmids used. C/EBP␣ has been shown to interact with Cdk2 and Cdk4, 2 proteins whose enzymatic activity is crucial for cell cycle progression. The interaction with Cdk2 prevents cyclin binding, an essential step in Cdk2 activation and G1 to S phase cell cycle progression, thereby resulting in cell cycle arrest. The inability of the ⌬177-191-C/EBP␣ mutant to induce cell cycle arrest was not caused by a defect in its DNA binding function. 23 This finding raised the possibility that the ⌬177-191 mutant might be able to induce granulocytic differentiation if inhibition of proliferation dependent on Cdk2 binding was essential for the effect. However, this mutant was as effective as wild-type C/EBP␣ in promoting granulocytic differentiation, in interacting with the C/EBP␣ binding sites of the G-CSFR and NE gene promoters, and in inducing luciferase activity from a G-CSFR promoter and NE mRNA expression in primary marrow cells and C/EBP␣ knock-out cells. Thus, the binding to Cdk2 and the possible growth suppression achieved by this mechanism do not seem to be required for granulocytic differentiation, although it cannot be excluded that they are important in differentiation of other cell types.
Timchenko et al 21, 22 have shown also that C/EBP␣ directly interacts with p21. Through this interaction, C/EBP␣ might enhance the p21 inhibitory activity on Cdk2/Cdk4, thus leading to growth arrest, [21] [22] [23] although there is evidence that C/EBP␣ can arrest proliferation of p21 Ϫ/Ϫ mouse embryo fibroblasts. 33 C/EBP␣-mediated growth arrest may be also enforced through proteasomedependent degradation of Cdk4. 34 Consistent with the observations that C/EBP␣ inhibits proliferation by its effects on several cell cycle regulators, Harris et al 24 showed that the DNA binding ability of C/EBP␣ was not required for C/EBP␣-mediated growth arrest as the Lys298Glu mutant remained able to induce growth arrest in fibroblast cell lines. We have extended these observations by assessing the effects of Lys298Glu-C/EBP␣ in granulocytic differentiation of hematopoietic cells. Consistent with the findings of Harris et al 24 that the Lys298Glu mutant was unable to activate transcription of a reporter gene driven by C/EBP␣ binding sites, we demonstrated that Lys298Glu does not bind to the G-CSFR and NE promoters and does not activate C/EBP␣-dependent gene expression. Moreover, the absence of C/EBP␣-dependent gene induction correlated with the inability to promote granulocytic differentiation, further indicating that the DNA binding function of C/EBP␣ is a critical requirement for the induction of granulocytic differentiation. Therefore, although the DNA binding activity may not be required for growth arrest induced by C/EBP␣, it appears to be crucial for C/EBP␣-dependent gene induction and granulocytic differentiation. The inability of the Lys298Glu mutant to induce granulocytic differentiation is consistent with a dominant-negative effect. This mutant cannot bind DNA (Figure 3 ) but can still dimerize through its bZIP domain, as it can form homodimers and heterodimers with itself and WT C/EBP␣, respectively (data not shown and Figure 5B ). Therefore, it is likely that ectopically expressed Lys298Glu-C/EBP␣ suppresses the function of the endogenous C/EBP␣ via a dominant-negative effect.
Another cell cycle regulator that was shown to be inhibited by C/EBP␣ is E2F, as indicated by C/EBP␣ repression of E2F-dependent transcription. 25, 26 C/EBP␣ can directly bind E2F, but this binding does not interfere with the DNA binding function of E2F. 25, 26 The binding of C/EBP␣ does affect E2F transcription activity that can also result in repression of c-Myc, and this effect might be important for granulocytic differentiation. 20 The BRM-2 mutant contains 2 amino acid mutations in the basic region that have been shown to mediate, in part, the physical association of C/EBP␣ with E2F. 26 Porse et al 26 have shown that knock-in BRM-2 mice that lack endogenous C/EBP␣ display abnormal adipocyte and granulocyte differentiation. The mutant failed to bind E2F in vitro and in vivo, but neither the ability to bind DNA nor the capacity to activate target gene expression in vivo were detectably affected in adipocyte tissue. 26 In our studies, the BRM-2 mutant was unable to induce granulocytic differentiation in each cell culture system. This mutant interacted with E2F-1 but failed to efficiently transactivate luciferase expression from a C/EBP␣ target gene promoter ( Figure 4A ) and to induce C/EBP␣-dependent gene expression (Figures 4 and 6) even if it was able to interact with C/EBP␣ DNA binding sites as assessed by EMSA (Figures 3 and 6B) . That E2F-1 interacted with BRM-2 C/EBP␣ was surprising, based on the study of Porse et al. 26 However, BRM-2 C/EBP␣ retains a region of interaction with E2F in its N-terminus, 26 suggesting that this segment may be responsible for E2F-1 binding in our assay. We are presently testing whether BRM-2 C/EBP␣ interacts with other members (E2F-2 and E2F-3) of the E2F family, which are required for proliferation of mammalian cells 35 and could interfere with myeloid cell differentiation, if constitutively active.
We do not have yet an explanation for the inability of BRM-2 C/EBP␣ to activate gene expression. The BRM-2 mutant did not differ from the WT protein in its affinity for C/EBP␣ binding sites. However, BRM-2-C/EBP␣ ectopically expressed in 32D-BCR/ ABL 6:15 cells formed a DNA-protein complex more slowly migrating than that involving p42 C/EBP␣ ( Figure 6B ). This DNA-protein complex of altered mobility was specific because 32D-BCR/ABL 6:15 cells do not express endogenous C/EBP␣ and C/EBP␤, and the complex was supershifted by an anti-C/EBP␣ antibody. Whether formation of this altered complex is linked to the inability of BRM-2 to activate gene expression and induce differentiation is a question that can be addressed on identification of the proteins present in the BRM-2-containing complex.
C/EBP␣ is a lineage-determining transcription factor that modulates gene expression and suppresses proliferation by DNA bindingdependent and -independent mechanisms. Moreover, C/EBP␣ dysregulation and gene mutation have been implicated in the development of acute myeloid leukemias 8 and in transition of chronic-phase CML to blast crisis, 14 emphasizing the importance of understanding the mechanisms whereby C/EBP␣ functions during myeloid differentiation. By a structural-functional analysis, we have demonstrated here that the DNA binding and transactivation domains are required for the differentiationinducing function of C/EBP␣. Although C/EBP␣ appears to suppress proliferation by interfering with the activity of several cell cycle regulators, our study does not support the importance of these mechanisms in granulocytic differentiation.
In conclusion, induction of gene expression appears to be the primary mechanism underlying C/EBP␣ regulation of granulocytic differentiation. However, it is not yet clear if this mechanism is also required for induction of cell cycle arrest, a function that at least in myeloid cells, is insufficient to promote differentiation independent from modulation of gene expression.
